In the last decade we have witnessed tremendous advances in our understanding of the landscape of the molecular alterations that underpin many of the most prevalent cancers, in the use of automated high - throughput platforms for high - throughput drug screens in cancer cells, in the creation of more
clinically relevant cancer cell models, and lastly in the development of more
useful computational approaches in the pursuit of
biomarkers of drug response.